Skip to Content

Stcube Inc 052020

Morningstar Rating
KRW 6,560.00 −180.00 (2.67%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

052020 is trading at a 54% discount.
Price
KRW 5,228.62
Fair Value
KRW 18,937.33
Uncertainty
Extreme
1-Star Price
KRW 188,434.57
5-Star Price
KRW 171.78
Economic Moat
Hhvbx
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 052020 is a good fit for your portfolio.

Trading Information

Previous Close Price
KRW 6,740.00
Day Range
KRW 6,500.007,350.00
52-Week Range
Bid/Ask
KRW 6,520.00 / KRW 6,560.00
Market Cap
KRW 312.04 Bil
Volume/Avg
1.3 Mil / 443,833

Key Statistics

Price/Earnings (Normalized)
Price/Sales
53.03
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Stcube Inc is a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in Korea.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
13

Comparables

Valuation

Metric
052020
310210
323990
Price/Earnings (Normalized)
Price/Book Value
8.977.814.52
Price/Sales
53.03730.35
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
052020
310210
323990
Quick Ratio
8.874.8554.78
Current Ratio
9.334.9155.43
Interest Coverage
−270.58−18.54−260.75
Quick Ratio
052020
310210
323990

Profitability

Metric
052020
310210
323990
Return on Assets (Normalized)
−43.51%−42.78%−29.47%
Return on Equity (Normalized)
−54.60%−96.10%−30.90%
Return on Invested Capital (Normalized)
−54.02%−44.97%−33.70%
Return on Assets
052020
310210
323990
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXdcbcknzsThvj$566.6 Bil
VRTX
Vertex Pharmaceuticals IncYtpyvxsfwQybly$102.4 Bil
REGN
Regeneron Pharmaceuticals IncJcflhgxtkLyjzk$98.3 Bil
MRNA
Moderna IncDwqdyfgQdk$42.7 Bil
ARGX
argenx SE ADRQglnljkFbgb$22.2 Bil
BNTX
BioNTech SE ADRYrbwmgpdtHcyzs$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncTxjfdpmfvLysxrsd$18.6 Bil
BMRN
Biomarin Pharmaceutical IncJbpnntqrQdhrw$15.6 Bil
RPRX
Royalty Pharma PLC Class ALscmlccnqqCbpqdsj$12.7 Bil
INCY
Incyte CorpJybwxgzQkwyb$11.8 Bil

Sponsor Center